Pfizer and Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment Pharmaceutical Investing
Alert: Johnson Fistel Investigates Proposed Sale of MyoKardia; Is $225 a Fair Price? Biotech Investing
Gilead Presents Biktarvy® Findings From Switch Studies & Analysis of Real-World BICSTaR Study At HIV Glasgow 2020 Biotech Investing
Bristol Myers Squibb Announces Update on CheckMate -915 Evaluating Opdivo Plus Yervoy Versus Opdivo in Resected High-Risk Melanoma Patients Biotech Investing
U.S. Food and Drug Administration Approves Opdivo® + Yervoy® as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma Biotech Investing
Algernon Announces 75% Enrollment in Multinational Phase 2b/3 Human Study of Ifenprodil for Treatment of COVID-19 Biotech Investing
